New CSL CEO Signals Stay-The-Course Strategy, No M&As
This article was originally published in PharmAsia News
Executive Summary
CSL's new CEO Paul Perreault offers a disappointing plan for anyone expecting a merger-and-acquisition strategy or a revamp of the Australia drug manufacturer’s approach.